

November 10, 2021



## NeoGenomics Appoints Dave Daly to Its Board of Directors

**FT. MYERS, FL / ACCESSWIRE / November 10, 2021 / NeoGenomics, Inc.**

**(NASDAQ:NEO)**, a leading provider of cancer-focused genetic testing services and global oncology contract research services, has appointed Dave Daly to serve on its Board of Directors.

Dave Daly joined our Board of Directors effective November 10, 2021. Mr. Daly currently serves as the President and Chief Operating Officer at Singular Genomics, a novel next generation sequencing and multi-omics technology platform company. Prior to Singular Genomics, Mr. Daly served as Chief Executive Officer at Thrive Earlier Detection, a liquid biopsy focused cancer screening company that was acquired by Exact Sciences Corporation for \$2.15 Billion in total consideration in early 2021. During the course of his extensive career in diagnostics, Mr. Daly has also served in key leadership roles at Illumina where he was Senior Vice President and General Manager of Commercial Operations for the Americas Region, Foundation Medicine where he was Chief Commercial Officer, Life Technologies where he led the oncology business unit, and Clariant where he served as Chief Commercial Officer. Mr. Daly has also held positions with Roche Diagnostics and Abbott Laboratories. Mr. Daly holds a BA in Economics from the University of California, Irvine and an MA in Economics from the University of California, Santa Barbara.

"We are delighted to welcome Dave Daly to our Board of Directors. He brings decades of experience in leadership roles at highly innovative companies in oncology diagnostics which will be critical as we enter the next stage of our ambitious growth strategy. Importantly, Dave shares our company's vision and values and his expertise will enhance our ability to better serve our clients and improve care for patients everywhere." said Lynn Tetrault, Non-Executive Chair of the Board of NeoGenomics.

"Having spent my career in the oncology diagnostic arena, I have long followed the progress of NeoGenomics and have admired the position the company has built as a leader in the space. I am pleased to be joining the NeoGenomics board at a pivotal moment in the company's history and I am happy to contribute my knowledge and experience as NeoGenomics transitions to the role of innovator in certain important technological areas." said Dave Daly, Board Member of NeoGenomics.

### **About NeoGenomics, Inc.**

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.

NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to all relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our [Notice of Privacy Practices](#), and has invested in leading technologies to ensure the data we maintain is secured at all times.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Cambridge, United Kingdom; Rolle, Switzerland; and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

### **Forward Looking Statements**

Certain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "would," "may," "will," "believe," "estimate," "forecast," "goal," "project," "plan," "potential" and other words of similar meaning. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward-looking statements as the result of the Company's ability to continue gaining new customers, respond to the effects of the COVID-19 outbreak, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, as well as additional factors discussed under the heading "Risk Factors" and elsewhere in the Company's Annual Report on Form 10-K filed with the SEC on February 25, 2021, as such information has been updated in subsequent SEC filings. . As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. NeoGenomics routinely posts information that may be important to investors in the "Investor Relations" section of its website at [www.neogenomics.com](http://www.neogenomics.com). The Company encourages investors and potential investors to consult the NeoGenomics website regularly for important information about NeoGenomics.

Forward-looking statements speak only as of the date such statements are made (unless another date is indicated) and should not be relied upon as of any subsequent date. While the Company may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

### **For further information, please contact:**

#### **NeoGenomics, Inc.**

Doug Brown

Chief Strategy and Corporate Development Officer

T: 239.768.0600 x2539

M: 704.236.2064

[doug.brown@neogenomics.com](mailto:doug.brown@neogenomics.com)

Charlie Eidson  
Director, Investor Relations and Corporate Development  
T: 239.768.0600 x2726  
M: 952.221.8816  
[charlie.eidson@neogenomics.com](mailto:charlie.eidson@neogenomics.com)

**SOURCE:** NeoGenomics, Inc.

View source version on accesswire.com:

<https://www.accesswire.com/672067/NeoGenomics-Appoints-Dave-Daly-to-Its-Board-of-Directors>